borderline significantP = 0.07
Furthermore, for HbA 1c there was a significant interaction between treatment groups and use of lipid lowering medication ( P < 0.05), which was also borderline significant for HS-CRP ( P = 0.07).
Furthermore, for HbA 1c there was a significant interaction between treatment groups and use of lipid lowering medication ( P < 0.05), which was also borderline significant for HS-CRP ( P = 0.07).